Timothy J Turner
Overview
Explore the profile of Timothy J Turner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gruber R, Wirak G, Blazier A, Lee L, Dufault M, Hagan N, et al.
Nat Commun
. 2024 Nov;
15(1):10116.
PMID: 39578444
Neuroinflammation in the central nervous system (CNS), driven largely by resident phagocytes, has been proposed as a significant contributor to disability accumulation in multiple sclerosis (MS) but has not been...
2.
Turner T, Brun P, Gruber R, Ofengeim D
Drugs R D
. 2024 Jul;
24(2):263-274.
PMID: 38965189
Background And Objectives: Tolebrutinib is a covalent BTK inhibitor designed and selected for potency and CNS exposure to optimize impact on BTK-dependent signaling in CNS-resident cells. We applied a translational...
3.
Kramer J, Bar-Or A, Turner T, Wiendl H
Nat Rev Neurol
. 2023 Apr;
19(5):289-304.
PMID: 37055617
Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated worsening of disability, which is assumed to be mainly associated with transient infiltration of peripheral immune cells into the...
4.
Teriflunomide Inhibits JCPyV Infection and Spread in Glial Cells and Choroid Plexus Epithelial Cells
OHara B, Gee G, Haley S, Morris-Love J, Nyblade C, Nieves C, et al.
Int J Mol Sci
. 2021 Sep;
22(18).
PMID: 34575975
Several classes of immunomodulators are used for treating relapsing-remitting multiple sclerosis (RRMS). Most of these disease-modifying therapies, except teriflunomide, carry the risk of progressive multifocal leukoencephalopathy (PML), a severely debilitating,...
5.
Enose-Akahata Y, Ngouth N, Ohayon J, Mandel M, Chavin J, Turner T, et al.
Neurol Neuroimmunol Neuroinflamm
. 2021 Apr;
8(3).
PMID: 33837058
Objective: To test the hypothesis that teriflunomide can reduce ex vivo spontaneous proliferation of peripheral blood mononuclear cells (PBMCs) from patients with human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical...
6.
Turner T
J Neurosci
. 2004 Dec;
24(50):11328-36.
PMID: 15601939
A major factor underlying compulsive tobacco use is nicotine-induced modulation of dopamine release in the mesolimbic reward pathway (Wise and Rompre, 1989). An established biochemical mechanism for nicotine-enhanced dopamine release...
7.
Zhou Y, Turner T, Dunlap K
J Physiol
. 2003 Feb;
547(Pt 2):497-507.
PMID: 12562906
Tottering, a mouse model for absence epilepsy and cerebellar ataxia, carries a mutation in the gene encoding class A (P/Q-type) Ca2+ channels, the dominant exocytotic Ca2+ channel at most synapses...
8.
Washburn K, Turner T, Talamo B
Chem Senses
. 2002 Aug;
27(7):635-42.
PMID: 12200344
Calcium plays an important regulatory role in olfactory signal transduction. Many investigations into the regulation of the olfactory signaling pathway have been performed using fractions enriched in ciliary membranes from...
9.
Polzin A, Shipitsin M, Goi T, Feig L, Turner T
Mol Cell Biol
. 2002 Feb;
22(6):1714-22.
PMID: 11865051
The Ral proteins are members of the Ras superfamily of GTPases. Because they reside in synaptic vesicles, we used transgenic mice expressing a dominant inhibitory form of Ral to investigate...